Alliance Global Partners raised the firm’s price target on Curaleaf to C$12 from C$9.50 and keeps a Buy rating on the shares. Curaleaf reported Q1 results broadly in-line with the firm’s expectations, says the analyst, who contends that Curaleaf “stands as one of the biggest beneficiaries” of rescheduling and Florida.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.